BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  Drug pricing

  10 Best-Selling Drugs of 2024 Rake in Billions Amid Exclusivity Threats

  Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its market share to biosimilar competitors.

  March 5, 2025

   · 

  11 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights

  Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

  March 5, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Podcasts

  Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More

  Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie and Eli Lilly strike mid-sized deals in obesity and molecular glues, priority review vouchers set to take a hit and immuno-oncology matures.

  March 5, 2025

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Vaccines

  FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount

  The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC advisory committee meetings.

  March 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Novo Launches DTC Program for Wegovy, Cutting Price to $499 a Month

  Novo Nordisk’s NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less than half of its list price.

  March 5, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Regulatory

  Novo, Sanofi Hit With Anti-Competitive Probe in South Africa: Bloomberg

  The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to lower drug prices.

  March 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Jazz Expands Cancer Expertise With $935M Chimerix Buy

  At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.

  March 5, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Patents

  Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ

  The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.

  March 5, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Rare diseases

  Rare Disease Biotechs Left in a Lurch as Congress Fails To Renew Priority Review Program

  Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

  March 5, 2025

   · 

  9 min read

   · 

  Annalee Armstrong
• 

  Rare diseases

  Priority Review Vouchers: By the Numbers

  A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer them found that 2024 was the busiest year yet. Companies have disclosed spending $513 million on vouchers that were earned in 2024 so far.

  March 5, 2025

   · 

  1 min read

   · 

  Annalee Armstrong